← Back to Screener
Rapport Therapeutics, Inc. Common Stock (RAPP)
Price$37.14
Favorite Metrics
Price vs S&P 500 (26W)41.10%
Price vs S&P 500 (4W)37.15%
Market Capitalization$1.90B
All Metrics
Book Value / Share (Quarterly)$10.14
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.84
Price vs S&P 500 (YTD)26.75%
EPS (TTM)$-2.86
10-Day Avg Trading Volume0.40M
EPS Excl Extra (TTM)$-2.86
EPS (Annual)$-2.86
ROI (Annual)-23.00%
Cash / Share (Quarterly)$10.27
ROA (Last FY)-21.76%
EBITD / Share (TTM)$-3.19
Cash Flow / Share (Annual)$-1.84
P/B Ratio3.92x
P/B Ratio (Quarterly)2.98x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-36.38x
ROA (TTM)-27.27%
EPS Incl Extra (Annual)$-2.86
Current Ratio (Annual)26.17x
Quick Ratio (Quarterly)25.76x
3-Month Avg Trading Volume0.36M
52-Week Price Return306.86%
Revenue / Employee (TTM)$0
52-Week High$42.27
EPS Excl Extra (Annual)$-2.86
26-Week Price Return49.85%
Quick Ratio (Annual)25.76x
13-Week Price Return44.82%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)26.17x
Enterprise Value$1,845.213
Revenue / Employee (Annual)$0
Cash / Share (Annual)$10.27
3-Month Return Std Dev53.41%
Net Income / Employee (TTM)$-1
ROE (Last FY)-23.00%
EPS Basic Excl Extra (Annual)$-2.86
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.86
ROI (TTM)-28.85%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)271.77%
Year-to-Date Return30.88%
5-Day Price Return14.60%
EPS Normalized (Annual)$-2.86
Month-to-Date Return26.91%
EBITD / Share (Annual)$-3.19
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.86
P/B Ratio (Annual)2.98x
Book Value / Share (Annual)$10.14
Price vs S&P 500 (13W)41.96%
Beta1.70x
Revenue / Share (TTM)$0.00
ROE (TTM)-28.85%
52-Week Low$7.73
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.27
4.27
4.25
4.25
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RAPPRapport Therapeutics, Inc. Common Stock | — | — | — | — | $37.14 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Rapport Therapeutics is a clinical-stage biotechnology company developing small-molecule precision medicines for neurological and psychiatric disorders. Its lead program, RAP-219, is in clinical development for focal onset seizures, generalized tonic-clonic seizures, and bipolar mania. The company also maintains two discovery-stage nicotinic acetylcholine receptor programs targeting chronic pain and hearing disorders.